Measuring the quality of journals and journal articles: The impact factor tells but a portion of the story

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 7-25

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Commentary; Impact factor; Journal quality; Review

Indexed keywords

CLINICAL PRACTICE; HEMOSTASIS; HUMAN; INFORMATION PROCESSING; MEASUREMENT; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SOCIETY; PRIORITY JOURNAL; PUBLISHING; REVIEW; THROMBOSIS; TOTAL QUALITY MANAGEMENT;

DATA INTERPRETATION, STATISTICAL; HEMOSTASIS; HUMANS; PERIODICALS AS TOPIC; THROMBOSIS;

EID: 43149114239     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066030     Document Type: Review

References (90)

1. Garfield E. The history and meaning of the journal impact factor. JAMA 2006;295:90-93
2. Bergemann D. The impact factor game: counting goals or measuring fair play? Thromb Haemost 2006;96:105-106
3. Lippi G, Franchini M. The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost 2007;97:1049-1050
4. Favaloro EJ. More on the impact factor and thrombosis and haemostasis journals: benefits and limitations. Thromb Haemost 2007;98:475-476
5. Lee C, Kessler C, Barback J. Haemophilia: January 2008. Haemophilia 2008;14:1-4
6. Favaloro EJ. Medical research in New South Wales 1993-96 assessed by Medline publication capture. Med J Aust 1998; 169:617-622
7. Dunlop LC, Skinner MP, Bendall LJ, et al. Characterisation of gmp-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992;175:1147-1150
8. Favaloro EJ. Clinical application of the PFA-100®. Curr Opin Hematol 2002;9:407-415
9. Favaloro EJ. Collagen binding assay for von Willebrand Factor (VWF:CBA): detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-135
10. Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001;7:170-179
11. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen binding assay aids in the diagnosis of, and permits sensitive discrimination between, type I and type II von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2:285-291
12. Favaloro EJ, Facey D, Henniker A. Use of a novel Platelet Function Analyser (PFA-100™) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999;62:165-174
13. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999;13:185-204
14. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 1993;71:571-581
15. Favaloro EJ, Grispo L, Dinale A, Berndt M, von Koutts J. Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 1993;25:152-158
16. Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor: use of different assays can influence the diagnosis of von Willebrand's disease, depending on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. AmJ Clin Pathol 1995;104:264-271
17. Favaloro EJ, Moraitis N, Bradstock K, Koutts J. Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. Br J Haematol 1990;74: 385-394
18. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts Jon behalf of the RCPA Quality Assurance Program (QAP) in Hematology Scientific Hemostasis Advisory Panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multilaboratory survey. Thromb Haemost 1999;82:1276-1282
19. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
20. Mammen EF, Koets MH, Washington BC, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11:281-292
21. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(Suppl 2):113-121
22. Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother 1998;41(Suppl. A):17-24
23. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25
24. Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci 2000;13:239-245
25. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993;54:793-806
26. Mammen EF. Pathogenesis of venous thrombosis. Chest 1992;102:640S-644S
27. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994;78:545-554
28. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992;6:1247-1257
29. Jafri SM, Vanrollins M, Ozawa T, Mammen EF, Goldberg AD, Goldstein S. Circadian variation in platelet-function in healthy-volunteers. Am J Cardiol 1992;69:951-954
30. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y(12) receptor antagonist activity. Semin Thromb Hemost 2005;31:184-194
31. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y(12) adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31: 174-183
32. van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y(12) antagonists. Semin Thromb Hemost 2005;31:195-204
33. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1):49-60
34. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005;31:150-161
35. Boeynaems JM, Communi D, Gonzalez NS, et al. Overview of the P2 receptors. Semin Thromb Hemost 2005;31:139-149
36. Rak J, Milsom C, May L, et al. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32:54-70
37. Robson SC, Wu Y, Sun XF, et al. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005;31:217-233
38. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31:381-392
39. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456-471
40. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110
41. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32:11-23
42. Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32: 33-39
43. Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005;31:168-173
44. Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Semin Thromb Hemost 2005;31:162-167
45. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006;32:24-32
46. Favaloro EJ, Wong RCW, Silvestrini R, et al. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta(2)-glycoprotein I antibody testing. Semin Thromb Hemost 2005;31:73-84
47. Mannucci PM. Laboratory detection of inherited thrombophilia: a historical perspective. Semin Thromb Hemost 2005;31:5-10
48. Michiels JJ, Berneman Z, Van Bockstaele D, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32:174-207
49. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006; 32(Suppl 1):32-38
50. Kher N, Marsh JD. Pathobiology of atherosclerosis-a brief review. Semin Thromb Hemost 2004;30:665-672
51. Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost 2005;31:17-24
52. Gallus AS. Management options for thrombophilias. Semin Thromb Hemost 2005;31:118-126
53. Jafri SM, Metha TP. Periprocedural management of anticoagulation in patients on extended warfarin therapy. Semin Thromb Hemost 2004;30:657-664
54. Favaloro EJ. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Thromb Hemost 2005;31:11-16
55. Wong RCW, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost 2005;31:39-48
56. Rajagopal V, Bhatt DL. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Semin Thromb Hemost 2004;30: 649-656
57. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004; 30:273-284
58. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004;30:703-713
59. Andersen JC. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Semin Thromb Hemost 2004;30:609-618
60. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004;30: 683-696
61. Hertzberg MS. Genetic testing for thrombophilia mutations. Semin Thromb Hemost 2005;31:33-38
62. Tang DG, Conti CJ. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update. Semin Thromb Hemost 2004;30:109-118
63. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006;32:5-10
64. Bunnett NW. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin Thromb Hemost 2006;32(Suppl 1):39-48
65. Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Semin Thromb Hemost 2005;31:709-716
66. Michiels JJ, Gadisseur A, Budde U, et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost 2005;31:577-601
67. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura - then and now. Semin Thromb Hemost 2006;32:81-89
68. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32(Suppl 1):3-15
69. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005;31:681-690
70. Michiels JJ, Raeve HD, Berneman Z, et al. The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders. Semin Thromb Hemost 2006; 32:307-340
71. Lowe EJ, Werner EJ. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost 2005;31:717-730
72. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006;32(Suppl 1): 61-68
73. Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 2005;31: 691-699
74. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32:803-809
75. Pini M, Spyropoulos AC. Prevention of venous thromboembolism. Semin Thromb Hemost 2006;32:755-766
76. Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost 2006;32: 838-847
77. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ. Tumor lysis syndrome. Semin Thromb Hemost 2007;33: 397-407
78. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006;32:651-658
79. Bernardi E, Pesavento R, Prandoni P. Upper extremity deep venous thrombosis. Semin Thromb Hemost 2006;32:729-736
80. Stellos K, Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. Semin Thromb Hemost 2007;33:159-164
81. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33:313-320
82. Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. Semin Thromb Hemost 2007;33:128-135
83. Ho VT, Linden E, Revta C, Richardson PG. Hepatic venoocclusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007;33:373-388
84. De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Thromb Hemost 2006;32: 767-781
85. Daub K, Lindemann S, Langer H, et al. The evil in atherosclerosis: adherent platelets induce foam cell formation. Semin Thromb Hemost 2007;33:173-178
86. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007;33:515-523
87. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 2007;33:573-581
88. Prandoni P, Lensing AWA, Pesavento R. New strategies for the treatment of acute venous thromboembolism. Semin Thromb Hemost 2006;32:787-792
89. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007;33:350-354
90. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007;33:563-572